Escitalopram is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Vigonvita Life Sciences (1). The most-studied condition is Major Depressive Disorder (MDD).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
NCT06828887 · ClinicalTrials.gov ↗ · MDD
|
Phase 2 | Recruiting | Vigonvita Life Sciences | China |
|
Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder
NCT06692361 · ClinicalTrials.gov ↗ · Major Depressive Disorder (MDD), Depression - Major Depressive Disorder
|
Not applicable | Recruiting | Gang Wang | China |
|
Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder
NCT07480525 · ClinicalTrials.gov ↗ · Depression - Major Depressive Disorder
|
Not applicable | Recruiting | Peking University | China |
|
Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole
NCT06937476 · ClinicalTrials.gov ↗ · Major Depressive Disorder (MDD), Rumination
|
Not applicable | Active, closed | Central South University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Vigonvita Life Sciences | 1 |
| Gang Wang | 1 |
| Central South University | 1 |
| Peking University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Escitalopram as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Vigonvita Life Sciences (1), Gang Wang (1), Central South University (1) and Peking University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Escitalopram works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Escitalopram works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Escitalopram (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.